12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Pfizer preclinical data

Researchers at the University of California, San Francisco, Pfizer and Exelixis Inc. (NASDAQ:EXEL, South San Francisco, Calif.) reported data from mouse models of pancreatic cancer showing that simultaneous inhibition of c-Met and VEGF signaling reduced tumor invasiveness and metastasis, whereas inhibiting VEGF signaling alone increased invasion and metastasis of tumors. Specifically, mice...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >